Table 3.

Detailed clinical course of 14 patients with monomorphic epitheliotropic intestinal T-cell lymphoma treated with autologous or allogeneic HSCT.

Patient	Age	Sex	Lugano stage	1st line treatment	1st line treatment response	Salvage treatment	Relapse before HSCT	HSCT type	Clinical outcomes	Follow-up period
1	64	Male	IV	4 cycles of SMILE	CR	–	CR	Frontline auto-HSCT	Relapse → died owing to PD	12.1 mo
2	50	Female	IV	7 cycles of ProMACE/CytaBOM	CR	–	CR	Frontline auto-HSCT	Relapse → died owing to PD	18.3 mo
3	56	Male	II2	6 cycles of DL-ICE	CR	–	CR	Frontline auto-HSCT	Relapse → died owing to PD	13.4 mo
4	60	Male	II2	5 cycles of SMILE	CR	–	CR	Frontline auto-HSCT	Relapse → died owing to PD	25.3 mo
5	59	Male	IV	6 cycles of DL-ICE	CR	–	CR	Frontline allo-HSCT MMUD (1 antigen mismatch)	CR, alive	8.3 mo
6	47	Female	IV	6 cycles of EPOCH	CR	–	CR	Frontline allo-HSCT MSD	CR, alive	33.2 mo
7	60	Male	I	6 cycles of DL-ICE	CR	–	CR	Frontline allo-HSCT MUD	CR, alive	61.3 mo
8	37	Male	IV	6 cycles of EPOCH	SD	3ESHAP	CR	Salvage auto-HSCT*	CR, alive	29.9 mo
9	60	Male	IV	6 cycles of DL-ICE	CR→ Relapse	4EPOCH	PR	Salvage allo-HSCT FMT (haploidentical)	CR, died owing to septic shock	27.6 mo
10	58	Male	IV	3 cycles of EPOCH	PD	5ESHAP	PR	Salvage allo-HSCT FMT (haploidentical)	CR, died owing to septic shock	8.5 mo
11	48	Female	IV	4 cycles of CHOP	PD	3ESHAP→2EPOCH	PR	Salvage allo-HSCT MSD	Relapse → died owing to PD	14.6 mo
12	53	Female	IV	3 cycles of CHOP	PD	3IVAM→3DHAP	SD	Salvage allo-HSCT MSD	Relapse → died owing to PD	14.5 mo
13	68	Male	II2	6 cycles of ProMACE/CytaBOM	PD	6DL-ICE	CR	Salvage allo-HSCT MSD	CR, alive	17.2 mo
14	49	Male	IV	4 cycles of ProMACE/CytaBOM	PD	3DL-ICE	PR	Salvage allo-HSCT MUD	CR, alive	139.1 mo

Allo-HSCT, allogeneic hematopoietic stem cell transplantation; auto-HSCT, autologous hematopoietic stem cell transplantation; CR, complete response; FMT, family-mismatched donor transplantation; MSD, matched sibling donor; MUD, matched unrelated donor; MMUD, mismatched unrelated donor; PD, progressive disease; PR, partial response; SD, stable disease

*This patient achieved CR and subsequently underwent salvage auto-HSCT with cytokine-induced killer cell infusion as a clinical trial.

CHOP consists of cyclophosphamide, doxorubicin, vincristine, and prednisone. CHOEP consists of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone. DHAP consists of dexamethasone, high-dose cytarabine, and cisplatin. DL-ICE consists of dexamethasone, l-asparaginase, ifosfamide, carboplatin, and etoposide. EPOCH consists of etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin. ESHAP consists of etoposide, methylprednisolone, high-dose cytarabine, and cisplatin. IVAM consists of ifosfamide, etoposide, cytarabine, and methotrexate. ProMACE-CytaBOM consists of cyclophosphamide, doxorubicin, etoposide, bleomycin, vincristine, methotrexate, and prednisone. SMILE consists of dexamethasone, methotrexate, ifosfamide, l-asparaginase, and etoposide.